Maha Othman and Marc Carrier
May 10, 2025, 06:35
Maha Othman: Pleasure to Interview the Brilliant Dr. Marc Carrier at Our Latest Thrombosis Canada Clot Conversation Podcast
Professor Maha Othman, Co-Chairman SSC on Disseminated intravascular coagulopathy at International Society on Thrombosis and Haemostasis, shared a post on X:
“Pleasure to interview the brilliant Dr. Marc Carrier at our latest Thrombosis Canada clot conversation podcast. Extended anticoagulation with reduced-dose apixaban is noninferior to full-dose; preventing recurrent VTE in cancer patients while resulting in less bleeding.”
Quoting Thrombosis Canada‘s post:
“New study, new standard? Reduced-dose apixaban may change the game in cancer-associated thrombosis. Dr. Carrier explains why.
Listen here.”
Find more on Hemostasis Today.
-
Jan 12, 2026, 04:16Wolfgang Miesbach on VTE and Cancer: A 20-Year Signal That Can’t Be Ignored
-
Jan 12, 2026, 03:54Francine Freitas Fernandes on Transvaginal US for Pelvic Venous Disorders
-
Jan 12, 2026, 02:58Jara Garcia Ugaldebere Shares STORM-PE Results: Thrombectomy Plus Anticoagulation for Acute High-Risk PE
-
Jan 12, 2026, 02:54Discover the New Blood Project․ Enhanced Search, Browsing, and Learning Resources
-
Jan 12, 2026, 02:54Can Preoperative Iron Status Predict Severe Anemia After Bariatric Surgery?
-
Jan 12, 2026, 02:27Bryce Kerlin to Impact of Advanced Hemostasis/Thrombosis Fellowship Training at Haemophilia Publication
-
Jan 12, 2026, 02:21Martin Haluzík on Compariosn of Cardiovascular Outcomes Between Semaglutide and Dulaglutide Therapies
-
Jan 12, 2026, 01:55Frank Weinz on State-of-the-Art Thromboembolism Prophylaxis
-
Jan 12, 2026, 01:45Khurram Nasir on Where The Cholesterol Guidelines Are Headed